O6-(R)-ROSCOVITINE, R-2-(6-BENZYLOXY-9-ISOPROPYL-9H-PURIN-2-YLAMINO)-BUTAN-1-OL

Identification

Name
O6-(R)-ROSCOVITINE, R-2-(6-BENZYLOXY-9-ISOPROPYL-9H-PURIN-2-YLAMINO)-BUTAN-1-OL
Accession Number
DB04770
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 355.4341
Monoisotopic: 355.200825069
Chemical Formula
C19H25N5O2
InChI Key
HGADNQLEUZSUEJ-OAHLLOKOSA-N
InChI
InChI=1S/C19H25N5O2/c1-4-15(10-25)21-19-22-17-16(20-12-24(17)13(2)3)18(23-19)26-11-14-8-6-5-7-9-14/h5-9,12-13,15,25H,4,10-11H2,1-3H3,(H,21,22,23)/t15-/m1/s1
IUPAC Name
(2R)-2-{[6-(benzyloxy)-9-(propan-2-yl)-9H-purin-2-yl]amino}butan-1-ol
SMILES
[H][[email protected]@](CC)(CO)NC1=NC2=C(N=CN2C(C)C)C(OCC2=CC=CC=C2)=N1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UPyridoxal kinaseNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
4369502
PubChem Substance
46508756
ChemSpider
3572044
BindingDB
10910
HET
R6C
PDB Entries
1yhj

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.17 mg/mLALOGPS
logP3.23ALOGPS
logP3.26ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)14ChemAxon
pKa (Strongest Basic)3.35ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area85.09 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity102.41 m3·mol-1ChemAxon
Polarizability39.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.691
Caco-2 permeable-0.6534
P-glycoprotein substrateSubstrate0.7146
P-glycoprotein inhibitor INon-inhibitor0.7782
P-glycoprotein inhibitor IINon-inhibitor0.9614
Renal organic cation transporterNon-inhibitor0.8521
CYP450 2C9 substrateNon-substrate0.7957
CYP450 2D6 substrateNon-substrate0.7439
CYP450 3A4 substrateSubstrate0.5457
CYP450 1A2 substrateInhibitor0.622
CYP450 2C9 inhibitorInhibitor0.5088
CYP450 2D6 inhibitorNon-inhibitor0.6606
CYP450 2C19 inhibitorNon-inhibitor0.7961
CYP450 3A4 inhibitorInhibitor0.63
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.794
Ames testNon AMES toxic0.6376
CarcinogenicityNon-carcinogens0.8552
BiodegradationNot ready biodegradable0.9785
Rat acute toxicity2.4604 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9108
hERG inhibition (predictor II)Non-inhibitor0.5983
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
Hypoxanthines
Alternative Parents
Secondary alkylarylamines / Aminopyrimidines and derivatives / Alkyl aryl ethers / N-substituted imidazoles / Benzene and substituted derivatives / Heteroaromatic compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Hypoxanthine / Alkyl aryl ether / Aminopyrimidine / Secondary aliphatic/aromatic amine / Monocyclic benzene moiety / Benzenoid / Pyrimidine / N-substituted imidazole / Azole / Heteroaromatic compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Required for synthesis of pyridoxal-5-phosphate from vitamin B6.
Gene Name
PDXK
Uniprot ID
O00764
Uniprot Name
Pyridoxal kinase
Molecular Weight
35102.105 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 11, 2007 11:49 / Updated on December 01, 2017 15:32